Oncolytic virus · Kills target cells · developed by Genelux
Olvimulogene Nanivacirepvec (Olvi-Vec, GL-ONC1) is an attenuated, engineered oncolytic vaccinia virus that enters tumor cells, replicates within them and lyses them, releasing viral particles and tumor-associated antigens. It carries a Renilla luciferase-GFP reporter allowing bioluminescent and fluorescent tracking of infected tumor cells. It is studied in ovarian, fallopian tube and peritoneal cancers and in extensive-stage small cell lung cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05281471 | Phase 3 | Platinum-resistant Ovarian Cancer | Recruiting | GNLX |
| NCT07136285 | Phase 1/2 | SCLC, Extensive Stage | Recruiting | GNLX |
| NCT01443260 | Phase 1/2 | Peritoneal Carcinomatosis | Completed | GNLX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Endometrioid Ovarian CancerFallopian Tube CancerHigh-grade Serous Ovarian CancerOvarian Clear Cell CarcinomaPlatinum-refractory Ovarian CancerPlatinum-resistant Ovarian CancerPrimary Peritoneal CancerSCLC, Extensive StagePeritoneal Carcinomatosis
Updated Oct 11, 2026. Something wrong or missing? Report it on the GNLX page.
See GNLX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GNLX catalysts and pipeline →